^
Association details:
| Biomarker: | EGFR mutation + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TP53 mutations impair overall survival of TKI-treated patients with oncogene-driven NSCLC
Published date:
10/09/2018
Excerpt:
TP53 mutations were present at diagnosis in 34% (51/149) of EGFR+ and 19% (15/76) of ALK+ patients, and they were associated with inferior OS in both EGFR+ (24 vs. 40 months in median, p = 0.027) and ALK+ NSCLC (24 vs. 53 months, p = 0.001).
Source:
Title:
Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer
Excerpt:
Of the 42 patients with advanced NSCLC harboring EGFR mutations who received TKIs… non-resistance co-mutations in APC, ATM, CDKN2A, MET, TP53, and 5 (12%) had resistance concurrent mutations in KRAS, PIK3CA, PTEN and SMAD4…. Median OS in the absence of co-mutations and in the presence of non-resistance mutations was 18.1 and 16.8 months, respectively, while it was significantly reduced in the group with resistance mutations (7.7 months, HR=4.6, 95% CI=1.56-13.3, p=0.002, compared to the other two groups).
DOI:
10.21873/cgp.20216
